/C O R R E C T I O N -- Human Longevity, Inc./
SOUTH SAN FRANCISCO, Calif., June 17, 2025 /PRNewswire/ -- Human Longevity, Inc. (HLI), a global leader in precision medicine and proactive health, today announced an expansion of its $1 million pledge initiative—this time targeting late-stage pancreatic cancer. Building on the success of its recent prostate cancer commitment, HLI is advancing its mission to detect cancer earlier and improve outcomes for its members by offering financial and clinical support for those members diagnosed with late-stage pancreatic cancer while enrolled in its Executive Health and 100+ Longevity programs.
Driving Innovation in Early Detection
Through its Executive Health Program and 100+ Longevity Programs, Human Longevity has delivered care to over 10,000 members using a comprehensive platform that integrates whole genome sequencing, advanced imaging, and multiplex blood biomarker tracking.
These efforts have enabled the development of what HLI believes to be one of the most advanced early detection algorithms for pancreatic cancer available today, including a new proprietary DNA-based pancreatic cancer screening test.
In most cases, our multi-modal screening approach helps detect cancer at a stage when it is curable. But in the rare event that a member is diagnosed at a late stage, our $1 million pledge ensures they receive the most advanced care available—without the burden of financial barriers.
How the $1 Million Pledge Works
Eligible individuals must be active pledge participants in HLI's Executive Health Program or affiliated Longevity Programs for pancreatic cancer early screening. These programs include:
Whole genome sequencing
Whole-body MRI, with dedicated pancreatic imaging
Long-term blood biomarker analysis
A DNA-based pancreatic cancer screening blood test
Qualified members diagnosed with late-stage pancreatic cancer while under HLI's care will receive up to $1 million toward treatment, care coordination, and access to a network of top-tier oncology experts from leading medical institutions.
Transforming the Future of Pancreatic Cancer Care
Pancreatic cancer is one of the deadliest forms of cancer due to its lack of early symptoms and late detection. Human Longevity's initiative aims to shift this paradigm by detecting disease earlier—when it is most treatable. The pledge not only offers support to individuals but also accelerates advancements in cancer screening technology through continuous real-world data integration and machine learning.
About Human Longevity, Inc.
Human Longevity, Inc. is a pioneering biotechnology company at the forefront of genomics, AI, and advanced medical technologies to extend healthspan and revolutionize preventative care. By leveraging vast genomic data, metabolomics, advanced imaging, and AI-driven diagnostics, Human Longevity is transforming healthcare from disease management to proactive prevention through its Executive Health and other Longevity Programs. The company remains committed to advancing medical research, improving patient outcomes, and unlocking the full potential of genomics to address the world's most pressing health challenges.
Media Contactmedia@humanlongevity.com
https://www.humanlongevity.com/1mpancreatic/
View original content to download multimedia:https://www.prnewswire.com/news-releases/human-longevity-inc-expands-pancreatic-cancer-prevention-commitment-with-1-million-pledge-for-qualified-members-302483622.html
SOURCE Human Longevity, Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Epoch Times
2 hours ago
- Epoch Times
Malfunctioning Insulin Pumps Recalled After 59 Injuries
San Diego-based Tandem Diabetes Care, Inc. is voluntarily recalling insulin pumps used to manage blood sugar, the company said in an Aug. 12 announcement by the Food and Drug Administration. Insulin pumps are wearable devices that deliver insulin at predetermined doses at specific times. Such devices can feature alarm functions to alert users about various situations, such as issues with insulin delivery.
Business Insider
4 hours ago
- Business Insider
J.P. Morgan Reaffirms Their Buy Rating on Mebuki Financial Group, Inc. (7167)
J.P. Morgan analyst Takahiro Yano maintained a Buy rating on Mebuki Financial Group, Inc. yesterday and set a price target of Yen1,110.00. The company's shares closed yesterday at Yen912.20. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. According to TipRanks, Yano is a 5-star analyst with an average return of 33.1% and an 88.64% success rate. Yano covers the Financial sector, focusing on stocks such as Resona Holdings, Sumitomo Mitsui Holdings, and SBI Holdings. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Mebuki Financial Group, Inc. with a Yen1,110.00 average price target. Based on Mebuki Financial Group, Inc.'s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of Yen78.64 billion and a net profit of Yen9.12 billion. In comparison, last year the company earned a revenue of Yen67.73 billion and had a net profit of Yen11 billion
Yahoo
6 hours ago
- Yahoo
The rich already know how private equity mints money — and it's not from a 401(k)
The ultrawealthy are envied for many reasons. For instance, we wish we could access the same private-market investments that they favor. Now, after the White House issued an executive order on Aug. 7, you may be able to invest like the billionaires do. Homeowners rush to refinance as mortgage-rate plunge opens window of opportunity My wife and I are in our 50s and have $11 million. We're not leaving it to our kids. Is that wrong? You could receive up to $7,500 from the AT&T settlement. Here's how class-action suits work. But would you want to? The executive order allows ordinary retirement savers to invest in private assets and cryptocurrency. This will expand investment options for anyone with a 401(k) or similar tax-advantaged retirement plan. It is a big deal — opening part of America's $12.4 trillion defined-contribution market to private-asset managers. The largest private-equity firms and other asset managers are salivating at the opportunity to pitch this untapped market of retirement savers. Private assets encompass a range of investments that do not trade on a public exchange. Examples include hedge funds, private equity, private credit and infrastructure. The case for private assets is they can provide a buffer against inflation — plus steady returns. The downsides include high fees, illiquidity and complexity. The nation's biggest asset managers welcome the executive order. They want to develop funds that make private assets easier for people to buy, and argue that the added diversification serves savers' best interests. Larry Fink, chief executive of BlackRock BLK, says retirement savers should replace the traditional 60% stocks/40% bonds asset-allocation model with a 50/30/20 split: 50% stocks, 30% bonds and 20% private assets. Read: Larry Fink proposes an alternative to the 60/40 portfolio. It means more fees. Should you be excited about this widening menu of investment choices? It depends on whom you ask. Some investment professionals like the idea of making private assets more available to more people. 'Historically, a number of private-market strategies have produced higher performance and additional diversification in defined-benefit pensions,' says Peter von Lehe, head of investment solutions and strategy at Neuberger Berman. 'It's appropriate that a broader range of investors have access to private assets in their defined-contribution plans because of the potential for return and diversification that these long-term investments can provide.' However, von Lehe cautions that these investments are illiquid and 'have a higher degree of complexity.' He says his 'most appropriate use case' for private-market investments is through professionally managed target-date funds or other funds that allocate a percentage of defined-contribution money to these complex but potentially more lucrative alternatives. Read: Here's something the rich know about managing investment risk that can help you, too Financial advisers have differing views on the role of private assets in client portfolios. Steven Roge, a certified financial planner in Bohemia, N.Y., says private markets are not for everyone. 'It's for people in the wealth-accumulation phase, say 40 to 50 years old, who have a long time horizon and a high risk tolerance,' Roge says. 'And they have to be sophisticated enough to understand it. We know if they don't understand it, they may not stick with it.' Of the firm's 300 clients, he says that 'only about a dozen' fit the bill for adding private-market assets to their retirement accounts. Even with the expanded investment options that may result from the White House's action, Roge remains a fan of passive strategies for most investors. 'Indexing is how they will win over the long run,' he says. 'But some clients want something that's special and different' as they seek market-beating returns. Given the illiquidity of private assets, Roge anticipates setting expectations for those clients who tend to monitor their portfolio daily — and who engage in frequent trading. 'These private investments may only price four times a year,' Roge says. 'That's not enough action for certain clients who track their portfolio like a hawk.' In his personal portfolio, Roge uses private markets — especially private equity — to diversify his holdings. He says he allocates about 25% to alternative assets. 'It helps me sleep at night knowing my portfolio isn't being pushed around by the volatility of public markets,' he says. Roge adds that he is not concerned about the current high valuations of private-equity funds. 'The valuations [of private-equity funds] are more realistic than the erratic valuations we see in public markets on a daily basis,' he says. Other advisers are more skeptical of the White House executive order. 'It's less being done out of interest for the general public and more for private industry lobbying the [Trump] administration,' says Alex Ruda, an adviser in Silver Spring, Md. The executive order undoubtedly pleases asset managers and private-equity firms. For years, they've wanted to attract retirement savers' money. These savers bear primary responsibility for managing their 401(k) compared with today's older retirees, many of whom receive employer-funded defined-benefit pensions. While some younger savers enjoy picking their investments, others dread it. 'The average American worker isn't equipped to navigate these complex [private-market] investments,' Ruda says. 'And they may fall prey to a little performance chasing given where we are in the market cycle' — as private markets have outperformed publicly traded stocks since 2000. Ruda feels so strongly about not incorporating private assets into client portfolios that he's willing to forgo newcomers who express such interest. 'If I wanted to broaden my client base, I'd have to play to what they want,' he says. 'But I don't have to do that. So I'd say to them, 'I'm not the best fit.'' Read next: Here's what it's like to invest in private equity — and why you don't want it in your 401(k) More: As private equity enters retirement plans, is it too dangerous for average investors to jump in? I'm a senior who barely survives on $1,300 a month. No way could I live on $1,000. 'I am a senior citizen': My car needs $3,500 for repairs, but only has a trade-in value of $6,000. Do I bother fixing it?
